HE4 (HUMAN EPIDIDYMIS PROTEIN-4) WITH ROMA INDEX (FOR EPITHELIAL OVARIAN CANCER)

HE4 (HUMAN EPIDIDYMIS PROTEIN-4) WITH ROMA INDEX (FOR EPIThelial Ovarian Cancer) is a specialized diagnostic oncology panel designed to evaluate the likelihood of epithelial ovarian cancer in women presenting with a pelvic mass. This comprehensive test measures serum levels of Human Epididymis Protein-4 (HE4) and CA-125, which are then integrated using the Risk of Ovarian Malignancy Algorithm (ROMA) along with the patient's menopausal status to generate a personalized numerical risk score.

Measurement of the ROMA index provides direct clinical insight into the probability of finding epithelial ovarian cancer when assessing a pelvic mass. Because accurate preoperative risk stratification supports timely surgical and oncological intervention, specialized biochemical testing supplies essential clinical data for gynecologic oncology, gynecology, oncology, and internal medicine evaluations.

The test requires a blood specimen collected by a qualified person using standard serum separator containers under appropriate clinical conditions, followed by precise analysis using automated laboratory immunoassay techniques. Results must always be interpreted in conjunction with the patient's clinical presentation, imaging studies, and formal gynecological examinations.

Benefits of HE4 (HUMAN EPIDIDYMIS PROTEIN-4) WITH ROMA INDEX (FOR EPITHELIAL OVARIAN CANCER) Testing

• Provides a validated mathematical risk score (ROMA index) for epithelial ovarian malignancy.
• Combines HE4 and CA-125 biomarkers with menopausal status for enhanced diagnostic accuracy.
• Helps gynecologists and oncologists triage pelvic masses effectively.
• Aids in distinguishing epithelial ovarian cancer from benign pelvic conditions.
• Supports tracking of specialized oncological and surgical care plans.
• Complements transvaginal ultrasound scans and pelvic imaging evaluations.
• Utilizes precise laboratory immunoassay techniques for reliable quantitative results.
• Assists specialists in determining appropriate surgical staging or referral strategies.
• Provides dependable turnaround times to support specialized clinical care.
• Utilizes standard venous blood collection procedures under medical supervision.

Clinical Indications and Applications

Pelvic Mass Evaluation: The primary clinical indication is evaluating women presenting with a pelvic mass or adnexal lesion to determine the risk of epithelial ovarian cancer prior to surgery.

Clinical Assessment: The test is utilized when performing preoperative risk stratification in specialized gynecologic oncology settings.

Why Doctors Recommend This Test

Gynecologic oncologists, oncologists, gynecologists, and internal medicine specialists recommend this test when investigating complex pelvic masses or determining whether a patient requires referral to a specialized cancer center. It delivers essential algorithmic data required to guide safe clinical management.

Following proper blood collection guidelines will ensure a smooth and efficient testing procedure.

What Happens During The Procedure?

The collection procedure involves obtaining a blood specimen drawn from a vein by a qualified phlebotomist using a clean, standard collection container provided by the healthcare facility under appropriate supervision protocols.

Once obtained, the sample is tested in the laboratory using advanced immunoassay analyzers to quantify HE4 and CA-125 concentrations, which are then computed alongside the patient's menopausal status to calculate the ROMA score. The procedure takes only a few minutes.

Normal Reporting Time

The report for the HE4 (HUMAN EPIDIDYMIS PROTEIN-4) WITH ROMA INDEX (FOR EPITHELIAL OVARIAN CANCER) test is generally available within 24 to 48 hours due to standard laboratory processing times. Results must be reviewed promptly with the referring gynecologic oncologist or specialist.

Who Should Consider This Test?

• Women identified with a pelvic mass or adnexal cyst scheduled for surgical evaluation.
• Patients investigated for suspected epithelial ovarian cancer as directed by a clinician.

Understanding Test Results

Test results provide individual biomarker concentrations alongside a calculated ROMA index score, evaluated against established laboratory pre- and post-menopausal risk cutoff thresholds.

Normal/Low-Risk Findings: A ROMA score below the specific cutoff indicates a lower statistical probability of epithelial ovarian cancer.

Abnormal/High-Risk Findings: A ROMA score exceeding the cutoff indicates an increased likelihood of epithelial ovarian malignancy, signaling the need for evaluation by a gynecologic oncologist.

Clinical Limitations

The ROMA index is designed specifically for women with a pelvic mass who have not yet undergone surgery; it is not intended as a general screening tool for asymptomatic populations.

Important Safety Information

Severe pelvic pain, acute abdominal distention, or rapid clinical changes require immediate medical attention. Patients must consult their healthcare provider or specialist to interpret ROMA index findings.